{"groups":[{"description":"Participants undergo a conditioning regimen with cyclophosphamide, fludarabine, aldesleukin (interleukin-2), natural killer cell therapy, anti-thymocyte globulin, rituximab, thiotepa, and melphalan prior to transplantation of T-cell depleted HPC transplant on day 0 and CD45RA-depleted HPC transplant on day 1. Beginning Day 6 post-transplant, patients receive G-CSF daily until ANC recovers to normal level.\n\nCyclophosphamide: Given intravenously (IV)\n\nFludarabine: Given IV\n\nG-CSF: Given IV or subcutaneously (SQ)\n\nInterleukin-2: Given SQ\n\nMelphalan: Given IV\n\nThiotepa: Given IV\n\nRituximab: Given IV\n\nNatural killer cell therapy: Given IV\n\nT-cell depleted HPC transplant: T-cell depleted hematopoietic stem cells will be infused on day 0.\n\nCD45RA-depleted HPC transplant: CD45RA depleted stem cells will be infused on day 1.","id":"FG000","title":"Participants"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"6"}],"type":"Donors"},{"reasons":[{"groupId":"FG000","numSubjects":"4"}],"type":"Death"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"12"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"2"}],"type":"One Year Post-transplant"},{"achievements":[{"groupId":"FG000","numSubjects":"2"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"10"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"preAssignmentDetails":"Six enrolled participants were blood donors and did not undergo transplantation.","recruitmentDetails":"Twelve participants meeting eligibility criteria were enrolled at St. Jude Children's Research Hospital between November 2014 and February 2015."}